Xerosis, eczematous rash, severe pruritus, erythema and edema, and scaling
Conditions
Interventions
Observation Group for Treating Severe Atopic Dermatitis in Adults:None
Sponsors
Shenzhen Second People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. The subjects voluntarily participated in the study and signed the informed consent form; 2. Age between 18 and 75 years old, gender not restricted; 3. The subjects were diagnosed with atopic dermatitis (atopic eczema), and the atopic dermatitis was confirmed to meet the Hanifin & Rajka AD criteria (Appendix 1) during the screening process; diagnosed as moderate or severe AD patients according to the "Chinese Guidelines for the Diagnosis and Treatment of Atopic Dermatitis 2020 Edition" (moderate: SCORAD score 25-50 points, severe: SCORAD score > 50 points); 4. Patients considered suitable for using emabetuzumab for AD treatment by the researchers.
Exclusion criteria
Exclusion criteria: 1. Absolute lymphocyte count (ALC) < 0.5 × 10^9/L, absolute neutrophil count (ANC) < 1 × 10^9/L, or hemoglobin (Hb) < 80g/L; 2. Subjects with malignant tumors or a history of malignant tumors (except for skin non-metastatic basal cell or squamous cell carcinoma that has been fully treated or removed, or cervical carcinoma in situ), or other subjects with a known intrinsic condition that predisposes to hypercoagulability; 3. Subjects with a history of thrombotic events (TEs), including deep vein thrombosis (DVT), pulmonary embolism, cerebrovascular accident, etc., and other subjects with known intrinsic conditions that predispose to hypercoagulability; 4. Subjects in the acute or chronic bacterial/fungal/viral infection period (including local infections); 5. Subjects with active tuberculosis, hepatitis B, or hepatitis C; 6. Subjects with severe diseases of the heart, liver, kidney, or other systemic diseases; 7. Subjects who received or were exposed to any live or attenuated vaccines within 8 weeks before starting the study drug treatment, or are expected to receive such vaccines during the study treatment or within 6 weeks after discontinuation of the study drug; 8. Subjects planning to become pregnant (male subjects with a fertility plan for their female partners, except for those willing to use contraceptive measures), pregnant or lactating subjects; 9. Subjects who are allergic to the test drug or any component of the drug or any excipient; 10. Subjects who cannot complete the procedures required by the study; 11. Subjects who, in the opinion of the investigator, have any other conditions that are not suitable for participation in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Eczema Area and Severity Index; | — |
Secondary
| Measure | Time frame |
|---|---|
| IGA Score Sheet;Body Surface Area (BSA) Scoring Table;WI-NRS score;SCORAD Rating Scale; | — |
Countries
China
Contacts
Public ContactCuihong Lian
Shenzhen Second People's Hospital
Outcome results
None listed